World Health Organization site
Skip Navigation Links

Main
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register.
Register: ClinicalTrials.gov
Last refreshed on: 12 December 2020
Main ID:  NCT02446899
Date of registration: 14/05/2015
Prospective Registration: Yes
Primary sponsor: AstraZeneca
Public title: Efficacy and Safety of Anifrolumab Compared to Placebo in Adult Subjects With Active Systemic Lupus Erythematosus
Scientific title: A Multicentre, Randomised, Double-blind, Placebo-controlled, Phase 3 Study Evaluating the Efficacy and Safety of Anifrolumab in Adult Subjects With Active Systemic Lupus Erythematosus
Date of first enrolment: July 9, 2015
Target sample size: 373
Recruitment status: Completed
URL:  https://clinicaltrials.gov/show/NCT02446899
Study type:  Interventional
Study design:  Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Double (Participant, Investigator).  
Phase:  Phase 3
Countries of recruitment
Argentina Belgium Brazil Bulgaria Canada Czech Republic Czechia France
Germany Japan Korea, Republic of Lithuania Mexico Russian Federation Singapore South Africa
Spain United States
Contacts
Name:     Lilia Pineda, MD
Address: 
Telephone:
Email:
Affiliation:  Medical Science Director
Key inclusion & exclusion criteria

Inclusion Criteria:

1. Aged 18 through 70 years at the time of screening

2. Diagnosis of paediatric or adult SLE with a diagnosis of SLE according to the ACR 1982
revised criteria =24 weeks prior to signing the Informed Consent form (ICF)

3. Currently receiving at least 1 of the following:

1. Where prednisone is the single standard of care medication (ie, the subject is
not concurrently receiving any medication listed in inclusion criterion 3(c)), a
dose of oral prednisone =7.5 mg/day but =40 mg/day (or prednisone equivalent) for
a minimum of 8 weeks prior to Day 1. In addition, the dose of oral prednisone or
prednisone equivalent the subject is taking must be stable for a minimum of 2
weeks prior to randomisation

2. Where prednisone is not the single standard of care medication (ie, the subject
is concurrently receiving at least one medication listed in inclusion criterion
3(c), a dose of oral prednisone (=40 mg/day) (or prednisone equivalent) for a
minimum of 2 weeks prior to signing of the ICF. In addition, the dose of oral
prednisone or prednisone equivalent the subject is taking must be stable for a
minimum of 2 weeks prior to randomisation.

3. Any of the following medications administered for a minimum of 12 weeks prior to
signing the informed consent, and at a stable dose for a minimum of 8 weeks prior
to signing the informed consent and through Day 1:

(i) Azathioprine =200 mg/day (ii) Antimalarial (eg, chloroquine, hydroxychloroquine,
quinacrine) (iii) Mycophenolate mofetil =2 g/day or mycophenolic acid =1.44 g/day (iv)
Oral, subcutaneous (SC), or intramuscular methotrexate =25 mg/week (v) Mizoribine =150
mg/day

4. Fulfils at least 4 of the 11 ACR modified 1982 classification criteria for SLE, at
least 1 of which must be:

1. Positive antinuclear antibody (ANA) test at screening by immunofluorescent assay
(IFA) at the central laboratory with titre =1:80; OR

2. Anti-dsDNA antibodies at screening elevated to above normal (including
indeterminate), as per the central laboratory; OR

3. Anti-Smith (anti-Sm) antibody at screening elevated to above normal as per the
central laboratory

5. At Screening, Disease Activity Adjudication Group confirmation of:

SLEDAI-2K Criteria: SLEDAI-2K score =6 points and "Clinical" SLEDAI-2K score =4
points. The "Clinical" SLEDAI-2K is the SLEDAI-2K assessment score without the
inclusion of points attributable to any urine or laboratory results including
immunologic measures.

6. Must not have active or latent TB on either chest radiograph or by quantiferon gold
test

7. Day 1 "Clinical" SLEDAI-2K score =4 points

8. OCS dose stable for at least 2 weeks prior to randomisation

9. Stable SLE SOC treatment at the time of randomisation

10. Women of child-bearing potential must have a negative serum ß-hCG test at and negative
urine pregnancy test at randomisation prior to administration of investigational
product

Exclusion Criteria:

1. Receipt of any investigational product (small molecule or biologic agent) within 4
weeks or 5 half-lives prior to signing of the ICF, whichever is greater

2. Receipt of any of the following:

(a) Intra-articular, intramuscular or IV glucocorticosteroids within 6 weeks prior to
Day 1

3. History of, or current diagnosis of, a clinically significant non SLE-related
vasculitis syndrome.

4. Active severe or unstable neuropsychiatric SLE

5. Active severe SLE-driven renal disease

6. Diagnosis (within 1 year of signing the ICF) of mixed connective tissue disease or any
history of overlap syndromes of SLE or SSc.

7. History of, or current, inflammatory joint or skin disease other than SLE

8. History of any non-SLE disease that has required treatment with oral or parenteral
corticosteroids for more than 2 weeks within the last 24 weeks prior to signing the
ICF

9. 26.27. Known history of a primary immunodeficiency, splenectomy, or any underlying
condition that predisposes the subject to infection, or a positive result for human
immunodeficiency virus (HIV) infection confirmed by central laboratory at screening.
Subjects refusing HIV testing during the screening period will not be eligible for
study participation

10. Confirmed positive test for hepatitis B or hepatitis C

11. Any severe herpes infection at any time prior to Week 0 (Day 1)

12. Opportunistic infection requiring hospitalisation or intravenous antimicrobial
treatment within 3 years prior to randomization

13. History of cancer, apart from:

1. Squamous or basal cell carcinoma of the skin that has been successfully treated

2. Cervical cancer in situ that has been successfully treated



Age minimum: 18 Years
Age maximum: 70 Years
Gender: All
Health Condition(s) or Problem(s) studied
Active Systemic Lupus Erythematosus
Intervention(s)
Biological: Anifrolumab
Drug: Placebo
Primary Outcome(s)
Number of Participants Who Achieved the British Isles Lupus Assessment Group Based Composite Lupus Assessment (BICLA) Response at Week 52 [Time Frame: Baseline; Week 52]
Secondary Outcome(s)
Number of Participants With a Potentially Clinically Important Change From Baseline in Vital Sign Measurements [Time Frame: Baseline to end of study (Maximum of 60 weeks)]
Annualised Flare Rate Through 52 Weeks [Time Frame: Baseline to Week 52]
Number of Participants With a Potentially Clinically Important Change From Baseline in Clinical Laboratory Tests [Time Frame: Baseline to end of study (Maximum of 60 weeks)]
Number of Participants With =50% Reduction in Joint Counts at Week 52 in The Sub-group of Participants With =6 Swollen and =6 Tender Joints at Baseline [Time Frame: Baseline; Week 52]
Number of Participants With a =50% Reduction in Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) Activity Score at Week 12 in The Sub-Group of Participants With Baseline CLASI Activity Score of =10 [Time Frame: Baseline; Week 12]
Number of Participants Who Achieved and Maintained an Oral Corticosteroids (OCS) Dose of =7.5 mg/Day at Week 52 in the Sub-Group of Participants With Baseline OCS =10 mg/Day [Time Frame: Week 40; Week 52]
Number of Participants Who Achieved the British Isles Lupus Assessment Group Based Composite Lupus Assessment (BICLA) Response at Week 52 in the IFN Test-High Sub-group [Time Frame: Baseline; Week 52]
Number of Participants With One or More Adverse Events of Special Interest (AESIs) [Time Frame: Baseline to end of study (Maximum of 60 weeks)]
Number of Participants With One or More Adverse Events (AEs) [Time Frame: Baseline to end of study (Maximum of 60 weeks)]
Secondary ID(s)
D3461C00004
Source(s) of Monetary Support
Please refer to primary and secondary sponsors
Secondary Sponsor(s)
PRA Health Sciences
Ethics review
Results
Results available: Yes
Date Posted: 18/03/2020
Date Completed:
URL: https://clinicaltrials.gov/ct2/show/results/NCT02446899
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.6 - Version history